Abivax SA Sponsored ADR (ABVX) Price & Analysis

Compare

256 Followers

ABVX Stock Chart & Stats

$110.39

-$0.09(-1.29%)

At close: Jan 08 4:00 PM EST

$110.39

-$0.09(-1.29%)

Day’s Range― - ―

52-Week Range$4.77 - $112.50

Previous CloseN/A

Volume62.24K

Average Volume (3M)1.14M

Market Cap

$8.52B

Enterprise Value$513.05M

Total Cash (Recent Filing)$60.95M

Total Debt (Recent Filing)$98.71M

Price to Earnings (P/E)―

Beta2.50

Next Earnings

Dec 15, 2025

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.38

Shares Outstanding77,828,920

10 Day Avg. Volume1,135,905

30 Day Avg. Volume1,140,609

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)10.98

Price to Sales (P/S)41.30

P/FCF Ratio-2.88

Enterprise Value/Market Cap0.06

Enterprise Value/Revenue54.49

Enterprise Value/Gross Profit54.49

Enterprise Value/Ebitda-2.27

Forecast

1Y Price Target

$129.25

Price Target Upside17.08% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-3.16

Revenue Forecast (FY)$9.39M

Bulls Say, Bears Say

Bulls Say

Drug Efficacy And AdoptionObefazimod demonstrates impressive clinical response rates in patients with JAK failure, offering a potential option for those facing surgery with limited alternatives.

Market PotentialFeedback from 5 KOLs supports strong commercial potential for obefazimod in UC, with expectations for strong market uptake if approved.

Safety And TolerabilityObefazimod has a consistently clean safety profile with no new safety signals, reinforcing confidence in its use.

Bears Say

Financial HealthThe company faces a high annualized cash burn of $205.0 million, with approximately 2.5 years of cash remaining.

Abivax SA Sponsored ADR News

Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

11d ago

CAT

Abivax initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Abivax (ABVX) with an Outperform rating and $176 price target The company’s odds...

11d ago

ABVX

Abivax announces patient-reported outcomes from ABTECT trial

Abivax (ABVX) announced patient-reported outcomes from its Phase 3 ABTECT 8-week induction trials evaluating obefazimod in adult patients...

13d ago

ABVX

Positive Outlook for Abivax SA: Obefazimod’s Potential in Crohn’s Disease Drives Buy Rating

Abivax SA Sponsored ADR (ABVX) has received a new Buy rating, initiated by Wolfe Research analyst, Andy Chen....

11d ago

ABVX

Abivax initiated with an Overweight at Barclays

Barclays analyst Etzer Darout initiated coverage of Abivax (ABVX) with an Overweight rating and $142 price target The...

1M ago

ABVX

Abivax price target raised, named a ‘Best Idea’ at Guggenheim

Guggenheim raised the firm’s price target on Abivax (ABVX) to $150 from $101 and keeps a Buy rating...

1M ago

ABVX

Abivax price target raised to $120 from $112 at BTIG

BTIG raised the firm’s price target on Abivax (ABVX) to $120 from $112 and keeps a Buy rating...

1M ago

ABVX

Abivax’s Obefazimod: Promising Clinical Results and Market Potential Drive Buy Rating

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Abivax SA Sponsored ADR and keeping the...

1M ago

ABVX

Abivax announces ABTECT 1, ABTECT 2 trials met primary endpoint

Abivax (ABVX) SA announced results from the first of two late-breaking presentations at the United European Gastroenterology, UEG,...

1M ago

ABVX

Promising Phase 2b Results and Competitive Positioning Support Buy Rating for Abivax’s Obefazimod

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Abivax SA Sponsored...

2M ago

ABVX

Abivax price target raised to $114 from $95 at Citizens JMP

Citizens JMP raised the firm’s price target on Abivax (ABVX) to $114 from $95 and keeps an Outperform...

2M ago

ABVX

One new option listing on September 18th

New option listings for September 18th include – Abivax SA American Depositary Shares (ABVX). Published first on TheFly...

2M ago

ABVX

Abivax price target raised to $101 from $71 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Abivax (ABVX) to $101 from $71 and keeps an Overweight...

2M ago

ABVX

Abivax SA Reports Financial Results and Strategic Advances

Abivax SA Sponsored ADR ( ($ABVX) ) has released its Q2 earnings. Here is a breakdown of the...

2M ago

ABVX

ABVX FAQ

What was Abivax SA Sponsored ADR’s price range in the past 12 months?

Abivax SA Sponsored ADR lowest stock price was $4.77 and its highest was $112.50 in the past 12 months.

What is Abivax SA Sponsored ADR’s market cap?

Abivax SA Sponsored ADR’s market cap is $8.52B.

When is Abivax SA Sponsored ADR’s upcoming earnings report date?

Abivax SA Sponsored ADR’s upcoming earnings report date is Dec 15, 2025 which is in 28 days.

How were Abivax SA Sponsored ADR’s earnings last quarter?

Abivax SA Sponsored ADR released its earnings results on Sep 08, 2025. The company reported -$1.375 earnings per share for the quarter, missing the consensus estimate of -$0.929 by -$0.446.

Is Abivax SA Sponsored ADR overvalued?

According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Abivax SA Sponsored ADR pay dividends?

Abivax SA Sponsored ADR does not currently pay dividends.

What is Abivax SA Sponsored ADR’s EPS estimate?

Abivax SA Sponsored ADR’s EPS estimate is -0.7.

How many shares outstanding does Abivax SA Sponsored ADR have?

Abivax SA Sponsored ADR has 77,828,920 shares outstanding.

What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?

Abivax SA Sponsored ADR reported an EPS of -$1.375 in its last earnings report, missing expectations of -$0.929. Following the earnings report the stock price went down -0.833%.

Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?

Currently, no hedge funds are holding shares in ABVX

Abivax SA Sponsored ADR Stock Smart Score

Outperform

Company Description

Abivax SA Sponsored ADR

Abivax SA is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic treatments for inflammatory diseases and viral infections, including its lead product candidate ABX464, which is being investigated for the treatment of ulcerative colitis and other indications. The company operates primarily in the biotechnology sector, leveraging its proprietary technologies to discover and develop innovative therapies that address significant unmet medical needs.

Abivax SA Sponsored ADR (ABVX) Earnings & Revenues

Historic Earnings Reports

ABVX Stock 12 Month Forecast

Average Price Target

$129.25

▲(17.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","177":"$177","47.25":"$47.3","90.5":"$90.5","133.75":"$133.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$176.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$129.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$101.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,47.25,90.5,133.75,177],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.42,108.08,113.74000000000001,119.4,125.06,130.72,136.38,142.04000000000002,147.7,153.36,159.02,164.68,170.34,{"y":176,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.42,104.48384615384616,106.54769230769232,108.61153846153846,110.67538461538462,112.73923076923077,114.80307692307693,116.86692307692309,118.93076923076923,120.99461538461539,123.05846153846154,125.12230769230769,127.18615384615384,{"y":129.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.42,102.31076923076924,102.20153846153846,102.0923076923077,101.98307692307692,101.87384615384616,101.76461538461538,101.65538461538462,101.54615384615384,101.43692307692308,101.3276923076923,101.21846153846154,101.10923076923076,{"y":101,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.94,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >